Mara Gerloni PhD

Mara Gerloni, PhD, is a seasoned biotechnology executive, immunologist, and translational scientist with more than three decades of experience in oncology drug discovery, cancer immunotherapy, vaccine development, and gastrointestinal research. She currently serves as Global Head of Translational Science at Cosmo Pharmaceuticals, where she leads scientific initiatives spanning gastroenterology, oncology, dermatology, and innovative medical technologies.

Gerloni earned her doctoral training in Microbiology and Virology and completed advanced research at the University of California, San Diego, where she developed novel immunological approaches using antibody engineering and DNA-based vaccination strategies targeting infectious diseases. Her early research included collaborations focused on vaccine development and immune-based therapies.

Throughout her distinguished career, Gerloni has played leadership roles in the discovery and development of immunotherapies, cancer vaccines, and translational research programs. Her expertise spans cellular immunology, immune regulation, inflammatory diseases, infectious disease immunology, and oncology. She has contributed extensively to advancing scientific understanding of immune-mediated diseases and translating laboratory discoveries into clinical applications.

An accomplished researcher and scientific leader, Gerloni has authored nearly 100 scientific publications and has been cited widely for her work in immunology, inflammation, gastrointestinal disease, and therapeutic development. Her recent efforts have focused on advancing innovative treatments for digestive disorders, liver disease, colorectal cancer prevention, and dermatologic conditions through translational science and clinical research.

In addition to her scientific contributions, Gerloni is recognized for fostering multidisciplinary collaborations that bridge academia, biotechnology, and clinical medicine. Through her leadership at Cosmo Pharmaceuticals, she continues to drive the development of novel therapies and precision medicine approaches aimed at improving outcomes for patients worldwide.